Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, is proud of the successful placement of Dr. Stuart Hughes as Chief Executive Officer at Nuage Therapeutics S.L. (“Nuage”).
Cellestial Health, a pioneering pharmaceutical development spin-out from the University of Cambridge, has closed a £515,000 pre-seed equity funding round to accelerate the development of novel therapeutics targeting astrocytes, an often-overlooked cell type in the brain, with the first indication of Parkinson’s disease.
Microbiotica has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at Digestive Disease Week (DDW) 3rd – 6th May in San Diego.
Coulter Partners successfully completed a search assignment for Tozaro and is pleased to announce the placement of Dr. Jason Slingsby, MBA as Chief Executive Officer.
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with MTIP and Coramaze Technologies (Coramaze) and is pleased to announce the placement of Rob ten Hoedt as Chair of Coramaze’s Board of Directors.
Alchemab Therapeutics (Alchemab) today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
Symbiosis, a global biopharmaceutical CMO specialising in the sterile fill finish of injectable drug products has been awarded a 2025 King’s Award for Enterprise in the International Trade category.
Ikarovec, which is developing field-changing bicistronic gene therapies for ophthalmic diseases, appoints Dr Thomas Ciulla, expert in ophthalmology drug development, as President and CEO.
PIR International recently partnered with Monument Therapeutics in appointing Robert Radie as Non-Executive Chair and Dr. Heather Preston as an Advisory Board Member.
NCIMB Limited ("NCIMB") has secured a £1.7m investment from the Investment Fund for Scotland, managed by Maven Capital Partners (“Maven”) and the Scottish National Investment Bank.
Microbiotica has presented new data on the mechanism of action of MB097 at the American Association for Cancer Research (AACR) annual meeting held in Chicago, April 25-30.
RxCelerate, the Cambridge-based out-sourced drug discovery and development leader, has unveiled a world-class Scientific Advisory Board (SAB) for its rapidly growing antibody discovery group, RxBiologics.
Pioneer Group, leading developer of life science ecosystems, integrating infrastructure, investment, and venture support, and ZEISS, a global leader in optical and optoelectronic technology, have unveiled a strategic partnership.
MHRA has granted conditional marketing authorisation for Autolus' treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).
This week saw the publication of Engineering Biology Aspirations, the final output of Angela McLean’s Year of Engineering Biology. The report sets out an ambitious, forward-looking vision for the field, exploring how engineering biology could shape the future of everything from food and fashion to fuel and health.
Mosaic Therapeutics, Ltd, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies, announced the in-licensing of two clinical-stage oncology programs.
Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global license agreement.
